Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04199767 · ClinicalTrials.gov registry record · Phase 2
SNIFF Multi-Device Study 2
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04199767: Completed Phase 2 study, sponsored by Wake Forest University Health Sciences.
NCT04199767 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04199767, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture. This goal of this study is to measure how much insulin the device delivers to the cerebrospinal fluid (CSF). In addition, this study will look at the effects of insulin administered intra-nasally on memory, and on blood levels of insulin.
Primary Outcome
Change in cerebrospinal fluid insulin levels after receiving a 20 or 40 International Unit dose of insulin delivered with one of three devices
Interventions
- DRUG 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
- DRUG 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2020-11-03 |
| Phase | Phase 2 |
What the finished NCT04199767 record still lists
NCT04199767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) is the first listed.
NCT04199767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04199767 about?
NCT04199767 is a clinical study titled "SNIFF Multi-Device Study 2". The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture. This goal of this study is to measure how much insulin the device delivers to the cerebrospinal fluid (CSF). In addition, this stud...
What is the current status of trial NCT04199767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-07-16. Estimated completion is 2020-11-03.
What interventions are being tested in trial NCT04199767?
The interventions under investigation include: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) (DRUG), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) (DRUG).
Who is sponsoring clinical trial NCT04199767?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04199767's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI